BYT

BoYen Therapeutics is a clinical-stage biotechnology company based in Taiwan that specializes in the development of innovative small molecule therapeutics for oncology and autoimmune diseases. Founded in 2010 by Dr. Yi-Chih Wu, a former scientist at Bristol Myers Squibb, the company leverages a proprietary prodrug technology platform to optimize the delivery, safety, and efficacy of established and novel compounds. Its lead candidate, BY-101, is a prodrug of clofarabine currently in Phase 2 clinical trials for the treatment of Acute Myeloid Leukemia (AML), for which it has received U.S. FDA Orphan Drug Designation. The company's pipeline also includes BY-102 for multiple sclerosis and several preclinical candidates, such as BYT-3156, targeting solid tumors like bladder and colon cancers. BoYen Therapeutics is listed on the Emerging Stock Board of the Taipei Exchange.